Executive Summary
i. Implantable
Neurostimulation Products
a. Market Analysis
ii. Transcutaneous
Electrical Nerve Stimulation Products
a. Market Analysis
iii. Methodology
Exhibit ES-1: Selected
Neurologic Conditions, Prevalence and Potential Neurostimulation Patient Population
Exhibit ES-2: Neurostimulation
Products, Combined Market Forecast, 2009-2014
Exhibit ES-3: 2009,
Neurostimulation Products Market, Estimated Percentage of Sales, by Application
Exhibit ES-4: Neurostimulation
Products (Including Cochlear Implants), Market Forecast, 2009-2014
Exhibit ES-5: Transcutaneous
Electrical Nerve Stimulators, Market Forecast, 2009-2014
1.
OVERVIEW OF THE NERVOUS SYSTEM AND selected neurologic diseases/DISORDERS
1.1
The Nervous System
1.1.1 Sacral Nerves
1.1.2 Vagus Nerves
1.1.3 Neurons
1.1.4 Brain
1.1.5 Spine
1.2
Neurologic and Other Diseases/Disorders
1.2.1 Alzheimer’s Disease
1.2.1.1 Etiology
1.2.1.2 Incidence
1.2.1.3 Prevalence
1.2.1.4 Treatment Options
1.2.1.4.1 Drug Therapy
1.2.1.4.2 Neurostimulation
and Other Device-Based Therapies
1.2.1.4.3 Surgery
1.2.1.4.4 Prevention
1.2.2 Depression
1.2.2.1 Etiology
1.2.2.2 Incidence
1.2.2.3 Prevalence
1.2.2.4 Treatment Options
1.2.2.4.1 Drug Therapy
1.2.2.4.2 Neurostimulation
1.2.2.5 Prevention
1.2.3 Epilepsy
1.2.3.1 Etiology
1.2.3.2 Incidence
1.2.3.3 Prevalence
1.2.3.4 Treatment Options
1.2.3.4.1 Drug Therapy
1.2.3.4.2 Neurostimulation
1.2.3.4.3 Surgery
1.2.3.4.4 Prevention
1.2.4 Gastroparesis
1.2.4.1 Etiology
1.2.4.2 Incidence
1.2.4.3 Prevalence
1.2.4.4 Treatment Options
1.2.4.4.1 Drug Therapy
1.2.4.4.2 Neurostimulation
1.2.4.4.3 Surgery
1.2.4.4.4 Prevention
1.2.5 Obesity
1.2.5.1 Etiology
1.2.5.2 Incidence
1.2.5.3 Prevalence
1.2.5.4 Treatment Options
1.2.5.4.1 Drug Therapy
1.2.5.4.2 Neurostimulation
1.2.5.4.3 Surgery
1.2.5.4.4 Prevention
1.2.6 Incontinence
1.2.6.1 Etiology
1.2.6.2 Incidence
1.2.6.3 Prevalence
1.2.6.4 Treatment Options
1.2.6.4.1 Drug Therapy
1.2.6.4.2 Neurostimulation
1.2.6.4.3 Surgery
1.2.6.4.4 Prevention
1.2.7 Pain
1.2.7.1 Nociceptive Pain
1.2.7.2 Neuropathic Pain
1.2.7.3 Acute Pain
1.2.7.3.1 Etiology
1.2.7.3.2 Incidence
1.2.7.3.3 Prevalence
1.2.7.3.4 Treatment Options
1.2.7.3.4.1 Neurostimulation
1.2.7.4 Chronic Pain
1.2.7.4.1 Etiology
1.2.7.4.2 Incidence
1.2.7.4.3 Prevalence
1.2.7.4.4 Treatment Options
1.2.7.4.4.1 Drug Therapy
1.2.7.4.4.2 Neurostimulation
and Other Device-Based Therapies
1.2.7.4.4.3 Alternative
Therapies
1.2.7.4.5 Chronic Migraine
1.2.7.4.5.1 Neurostimulation
1.2.8 Parkinson’s Disease
1.2.8.1 Etiology
1.2.8.2 Incidence
1.2.8.3 Prevalence
1.2.8.4 Treatment Options
1.2.8.4.1 Drug Therapy
1.2.8.4.2 Neurostimulation
1.2.8.4.3 Surgery
1.2.8.4.4 Prevention
1.2.9 Other Neurologic Diseases/Disorders
Exhibit 1-1: United
States Population, by Age Group, Selected Years, 2000-2050
Exhibit 1-2: Selected
Neurologic Conditions, Prevalence and Potential Neurostimulation Patient
Population
Exhibit
1-3: The Sacral Nervous System
Exhibit
1-4: The Vagus Nerve
Exhibit
1-5: Anatomy of the Brain
Exhibit
1-6: Anatomy of the Spine
Exhibit
1-7: Alzheimer’s Disease, Facts and Figures
Exhibit
1-8: 2010, Alzheimer’s Disease Medications
Exhibit
1-9: Depression, Facts and Figures
Exhibit
1-10: Epilepsy, Facts and Figures
Exhibit
1-11: Gastroparesis, Facts and Figures
Exhibit
1-12: 2010, Obesity Comorbidities
Exhibit
1-13: Obesity, Facts and Figures
Exhibit
1-14: Urinary Incontinence, Facts and Figures
Exhibit 1-15: 2010,
Treatment Options for Urinary Incontinence
Exhibit
1-16: Acute Pain, Facts and Figures
Exhibit
1-17: Chronic Pain, Facts and Figures
Exhibit
1-18: Migraine Headache, Facts and Figures
Exhibit
1-19: Parkinson’s Disease, Facts and Figures
Exhibit
1-20: Essential Tremor, Facts and Figures
Exhibit 1-21: Obsessive-Compulsive
Disorder, Facts and Figures
Exhibit
1-22: Stroke, Facts and Figures
Exhibit 1-23: Obstructive
Sleep Apnea, Facts and Figures
Exhibit
1-24: Tinnitus, Facts and Figures
2.
NEUROSTIMULATION PRODUCTS MARKET
2.1
Implantable Neurostimulators
2.1.1 Cortical Stimulators
2.1.2 Deep Brain Stimulators
2.1.3 Gastric Nerve Stimulators
2.1.4 Sacral Nerve Stimulators
2.1.5 Spinal Cord Stimulators
2.1.6 Vagus Nerve Stimulators
2.1.7 Cochlear Implants
2.1.8 Hypoglossal Nerve Stimulators
2.1.9 Phrenic Nerve Stimulators
2.2 Core Treatment
Areas for Implantable Neurostimulators
2.2.1 Major Depression
2.2.1.1 Cyberonics
2.2.1.2 Medtronic
2.2.1.3 Northstar Neuroscience
2.2.1.4 St. Jude Medical
2.2.2 Epilepsy
2.2.2.1 Cyberonics
2.2.2.2 Integra LifeSciences
2.2.2.3 Medtronic
2.2.2.4 NeuroPace
2.2.2.5 NeuroVista
2.2.2.6 Victhom Human Bionics
2.2.3 Gastroparesis
2.2.3.1 Medtronic
2.2.4 Hearing Loss
2.2.4.1 Advanced Bionics/Sonova Holding
2.2.4.2 Cochlear
2.2.4.3 MED-EL
2.2.5 Incontinence
2.2.5.1 Medtronic
2.2.6 Pain
2.2.6.1 Boston Scientific
2.2.6.2 Medtronic
2.2.6.3 MicroTransponder
2.2.6.4 St. Jude Medical
2.2.7 Dystonia, Essential
Tremor, and Parkinson’s Disease
2.2.7.1 Medtrode
2.2.7.2 Medtronic
2.2.7.3 NeuroMEDx
2.2.7.4 St. Jude Medical
2.2.8 Sleep Apnea
2.2.8.1 Apnex Medical
2.2.8.2 Avery Biomedical Devices
2.2.8.3 Cardiac Concepts
2.2.8.4 ImThera Medical
2.2.8.5 Inspire Medical Systems
2.2.8.6 Synapse Biomedical
2.2.8.7 Victhom Human Bionics
2.3
Emerging Applications for Neurostimulation
2.3.1 Alzheimer’s Disease
2.3.1.1 Cyberonics
2.3.2 Blindness
2.3.2.1 Second Sight Medical Products
2.3.3 Chronic Headache
2.3.3.1 Boston Scientific
2.3.3.2 Medtronic
2.3.3.3 St. Jude Medical
2.3.4 Obesity
2.3.4.1 EnteroMedics
2.3.4.2 IntraPace
2.3.4.3 Johnson & Johnson
2.3.4.4 Leptos Biomedical
2.3.4.5 Medtronic
2.3.4.6 MetaCure
2.3.5 Obsessive-Compulsive Disorder
2.3.5.1 Medtronic
2.3.6 Stroke
2.3.6.1 Cyberonics
2.3.6.2 Northstar Neuroscience
2.3.7 Paralysis/Spinal Cord Injury
2.3.7.1 The BrainGate Company
2.3.7.2 NeuroMetrix
2.3.7.3 Össur with Victhom Human Bionics
2.3.7.4 Neurostream
Technologies/Otto Bock HealthCare and Victhom Human Bionics
2.3.8 Tinnitus
2.3.8.1 Silere Medical Technology
2.4
Market Forecast
2.5
Competitive Analysis
Exhibit 2-1: 2010,
Selected Advantages and Disadvantages of Neurostimulation Therapy
Exhibit 2-2: 2009,
Patients Who Have Received Neurostimulation Implants, by Selected Neurologic
Condition
Exhibit 2-3: 2010,
Established Neurostimulation Therapies and Leading Suppliers
Exhibit
2-4: Deep Brain Stimulation
Exhibit 2-5: Neurostimulation
in Suppressing Epileptic Seizures; NeuroPace’s Responsive Neurostimulator Therapy
Exhibit 2-6: Neurostimulation
in the Treatment of Gastroparesis, Medtronic’s Enterra
Exhibit
2-7: Cochlear’s Nucleus Freedom Implant
Exhibit
2-8: Medtronic’s InterStim Therapy System
Exhibit 2-9: Medtronic’s
Neurostimulators for the Treatment of Chronic Pain
Exhibit 2-10: St.
Jude Medical’s Neurostimulators for the Treatment of Chronic Pain
Exhibit 2-11: Medtronic’s
Activa Therapy for Parkinson’s Disease and Essential Tremor
Exhibit 2-12: 2010,
Selected Current and Emerging Neurostimulation Systems
Exhibit 2-13: Second
Sight Medical Products’ Intraocular Retinal Prosthesis
Exhibit 2-14: 2009,
Neurostimulation Products Market, Estimated Percentage of Sales, by Application
Exhibit 2-15: Neurostimulation
Products, Selected Market Drivers and Limiters
Exhibit 2-16: Neurostimulation
Products (Including Cochlear Implants), Market Forecast, 2009-2014
Exhibit 2-17: Neurostimulation
Products (Excluding Cochlear Implants), Market Forecast, 2009-2014
Exhibit 2-18: Cochlear
Implants, Market Forecast, 2009-2014
Exhibit 2-19: 2009,
Neurostimulation Products Market (Including Cochlear Implants), Share by
Supplier
Exhibit 2-20: 2009,
Neurostimulation Products Market (Excluding Cochlear Implants), Share by
Supplier
Exhibit 2-21: 2009,
Cochlear Implants Market, Share by Supplier
3.
Transcutaneous electrical nerve stimulation products market
3.1
Overview
3.1.1 Products
3.1.1.1 American Imex
3.1.1.2 BioMedical Life Systems
3.1.1.3 Dynatronics
3.1.1.4 Empi/DJO
3.1.1.5 Neuro Resource Group
3.1.1.6 RS Medical
3.1.1.7 Zynex Medical
3.1.2 Market Analysis
3.1.3 Competitive Analysis
3.2 Other
Noninvasive Electrical Stimulation Technologies
3.2.1 Transcranial
Magnetic Stimulation/Other Magnetic Stimulation
3.2.1.1 Neuralieve
3.2.1.2 The Magstim Company
3.2.1.3 Neotonus
3.2.1.4 Neuronetics
3.2.1.5 Nexstim
3.2.2 Electrotherapy Technologies
3.2.2.1 Innovative
Neurotronics/Hanger Orthopedic Group
3.2.2.2 Moeller Medical
3.2.2.3 Zynex Medical
Exhibit 3-1: 2010,
Selected Conditions That May Be Treated Using Transcutaneous Electrical Nerve
Stimulation
Exhibit 3-2: Dynatronics’
Sympathetic Therapy Systems
Exhibit 3-3: Zynex
Medical’s Transcutaneous Electrical Nerve Stimulation Systems
Exhibit 3-4: 2010,
Selected Transcutaneous Electrical Nerve Stimulation Devices
Exhibit 3-5: Transcutaneous
Electrical Nerve Stimulators, Market Forecast, 2009-2014
Exhibit 3-6: 2009,
Transcutaneous Electrical Nerve Stimulators Market, Share by Supplier
Exhibit 3-7: 2010,
Selected Transcranial and Other Magnetic Stimulation Systems
Exhibit
3-8: Innovative Neurotronics’ WalkAide
4. Company Profiles
4.1
Advanced Bionics Corporation/Sonova Holding AG
4.2
Apnex Medical, Inc.
4.3
BioMedical Life Systems, Inc.
4.4
Boston Scientific Corporation
4.5
Cochlear LTD
4.6
Cyberonics, Inc.
4.7
DJO, Inc.
4.8
Dynatronics Corporation
4.9
EnteroMedics, Inc.
4.10
MED-EL Corporation
4.11
Medtronic, Inc.
4.12
RS Medical, Inc.
4.13
Second Sight Medical Products, Inc.
4.14
St. Jude Medical, Inc.
APPENDIX: COMPANY
LISTING
